Compositions and Formulations of 9-Nitrocamptothecin Polymorphs and Methods of Use Therefor

A polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having, by differential scanning calorimetry, an endotherm at between 273.9 to 275.9° C., and an exotherm at between 279.3 and 281.3° C.

A polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having, for Cu Kα radiation of wavelength of 1.5406 Angstrom, an X-ray powder diffraction pattern with diffraction lines at °2θ values 4.8, 14.2, 19.1 and 26.8.

9-nitrocamptothecin in a form crystallized from acetonitrile.

A pharmaceutical composition comprising:

• a pharmaceutical carrier;
• and
• a polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having, by differential scanning calorimetry, an endotherm at between 273.9 to 275.9° C., and an exotherm at between 279.3 and 281.3° C.

A pharmaceutical composition comprising:

• a pharmaceutical carrier;
• and
• a polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having, by differential scanning calorimetry, an endotherm at between 273.9 to 275.9° C., and an exotherm at between 279.3 and 281.3° C.

A pharmaceutical composition comprising:

• a pharmaceutical carrier;
• and
• a polymorphic form of 9-nitrocamptothecin, the polymorph being characterizable as having, for Cu Kα radiation of wavelength of 1.5406 Angstrom, an X-ray powder diffraction pattern with diffraction lines at °2θ values 4.8, 14.2, 19.1 and 26.8.

A pharmaceutical composition comprising:

• a pharmaceutical carrier;
• and
• a polymorphic form of 9-nitrocamptothecin crystallized from acetonitrile.

A method of preparing a polymorphic form of 9-nitrocamptothecin, the method comprising:

• crystallizing 9-nitrocamptothecin from acetonitrile.